Fecal Impaction Clinical Trial
Official title:
Use of Gastrografin in the Management of Fecal Impaction in Patients With Severe Chronic Constipation: A Double-blinded Randomized Controlled Trial
Fecal impaction (FI) is a common cause of lower gastrointestinal tract obstruction, and it is the result of chronic or severe constipation and most commonly found in the elderly population. Gastrografin is a water soluble contrast mediate that could act as an osmotic laxative. It has been shown to confer a therapeutic beneļ¬t in adhesive small bowel obstruction (SBO). The investigators speculate that gastrografin administrated orally may be more effective than enema in the treatment of fecal impaction induced intestinal obstruction.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04579731 -
Development of Fecal Scoring for the Management of Fecal Impaction With Regards to Lower Urinary Tract Dysfunction
|
||
| Not yet recruiting |
NCT06349031 -
Comparison of Efficacy & Tolerability Of PEG 4000 Versus PEG 3350+ Electrolytes for Pediatric Fecal Disimpaction
|
Phase 4 | |
| Enrolling by invitation |
NCT04815226 -
The Role of Active Administration of Peristeen Bowel Evacuation for the Management of Urinary Tract Infection
|
N/A |